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Abstract
Aortic calcification is an important independent predictor of future cardiovascular events. We 
performed a genome-wide association meta-analysis to determine single nucleotide 
polymorphisms (SNPs) associated with the extent of abdominal (AAC, n = 9,417) or descending 
thoracic (TAC, n = 8,422) aortic calcification. Two genetic loci, HDAC9 and RAP1GAP, were 
associated with AAC at a genome-wide level (P < 5.0 × 10−8). No SNPs were associated with TAC 
at the genome-wide threshold. Increased expression of HDAC9 in human aortic smooth muscle 
cells (HASMCs) promoted calcification and reduced contractility, while inhibition of HDAC9 in 
HASMCs inhibited calcification and enhanced cell contractility. In matrix Gla protein (MGP)-
deficient mice, a model of human vascular calcification, mice lacking HDAC9 had a 40% 
reduction in aortic calcification and improved survival. This translational genomic study identifies 
the first genetic risk locus associated with calcification of the abdominal aorta and describes a 
novel role for HDAC9 in the development of vascular calcification.
Editorial summary
Genome-wide analyses identify variants near HDAC9 associated with abdominal aortic 
calcification and other cardiovascular phenotypes. Functional work shows that HDAC9 promotes 
an osteogenic vascular smooth muscle cell phenotype, enhancing calcification and reducing 
contractility.
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Arterial wall calcification is a hallmark of atherosclerosis and serves as an important factor 
for cardiovascular (CV) risk assessment1,2. Although studies have identified the genetic 
underpinnings of coronary artery calcification3,4 and valvular calcification5, the genetic 
determinants of human aortic calcification remain unknown. As with coronary artery 
calcification, both abdominal aortic calcification and thoracic aortic calcification are strong 
independent predictors of CV-related events and death6–8. A meta-analysis of studies of the 
CVD risk conferred by AAC found that individuals with the highest, compared to the lowest, 
tertile of AAC had a relative risk of 1.92 for coronary events and of 1.56 for cerebrovascular 
events9. Higher levels of AAC were associated with a >75% increase in CV mortality10. 
Aortic calcification is also associated with aortic aneurysms11 as well as maladaptive cardiac 
responses, such as left ventricular hypertrophy and diastolic dysfunction, caused by arterial 
stiffening12–14.
Identifying the genetic determinants of abdominal and thoracic aortic calcification may help 
elucidate novel mechanisms underlying vascular disease. We therefore performed a genome-
wide association study (GWAS) meta-analysis of cohorts within the Cohorts for Heart and 
Aging Research in Genome Epidemiology (CHARGE) consortium15. Subsequent 
association analyses were performed in multi-ethnic cohorts to validate genome-wide 
significant findings.
Individuals of European ancestry from five different cohorts (Framingham Heart Study, 
FHS; Age, Gene-Environment Susceptibility-Reykjavik Study, AGES-RS; Multi-Ethnic 
Study of Atherosclerosis, MESA; Family Heart Study, FamHS; and Heinz Nixdorf Recall 
study, HNR) were included in the discovery analysis. Baseline characteristics of the 
participants in the discovery analysis are provided in Supplementary Table 1. Quantification 
of the degree of vascular calcification from computed tomography (CT) scans was available 
for the abdominal aorta in 9,417 participants and for the descending thoracic aorta in 8,422 
participants. The validation stage of the study used data obtained from non-European 
ancestry groups in MESA (African American, n = 343; Hispanic American, n = 496), 
FamHS (African American, n = 621), and the African American-Diabetes Heart Study (AA-
DHS, n = 750).
The genomic inflation factor (λ) in the discovery meta-analysis was small for both AAC (λ 
= 1.09) and TAC (λ = 1.00), suggesting that potential genotyping artifact, cryptic relatedness 
in the population, or systematic differences in allelic distributions due to population 
stratification did not cause significant bias16. The quantile-quantile plots for the AAC and 
TAC meta-analyses (Fig. 1a and Supplementary Fig. 1, respectively) demonstrated that the 
observed distribution of P values for both vascular phenotypes matched the expected 
distribution.
SNPs associated with AAC were identified in two genetic loci (Fig. 1a–c and Table 1), the 
first encoding histone deacetylase 9 (HDAC9, hg38 chr7:18,086,949–18,666,929) and the 
second encoding RAP1 GTPase activating protein (RAP1GAP, hg38 chr1:21,596,221–
21,669,306). SNPs associated at a genome-wide significance level with AAC in the HDAC9 
locus were rs57301765, rs2107595, rs28688791, rs2023936, rs2526620, and rs7798197 
(Table 1). SNPs associated with AAC in the RAP1GAP locus included rs4654975 and 
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rs3767120; two additional SNPs (rs10159452 and rs10157126) were just below the 
threshold for genome-wide significance (P = 5.8–5.9 × 10−8). All of the SNPs associated 
with AAC are located in non-coding regions of their respective gene loci. The minor allele at 
each SNP was associated with a greater degree of AAC (Table 1), and both the magnitude 
and direction of association were consistent across all discovery stage cohorts (one 
representative SNP from each locus is highlighted in Supplementary Table 2). Additional 
SNPs (n = 14) with suggestive evidence for association with AAC (P < 1 × 10−6) are listed 
in Supplementary Table 3.
No SNPs were found to be associated with TAC at a genome-wide level of significance. 
There was evidence for borderline significance (P = 8.6 × 10−8) for one SNP on 
chromosome 9 (rs58674255) in the vacuolar protein sorting 13 homolog A (VPS13A) locus 
(Table 1 and Supplementary Fig. 1). Additional SNPs (n = 22) with suggestive evidence for 
association (P < 1 × 10−6) are listed in Supplementary Table 4.
SNPs that were associated with AAC in the discovery analysis were tested for association in 
independent validation cohorts. All six SNPs in the HDAC9 locus were significantly 
associated with AAC in an independent replication sample from MESA consisting of 
Hispanic Americans (n = 496, all P < 1.9 × 10−4), and exhibited the same direction of 
association as the discovery cohorts (Table 2). Of these six SNPs, rs2107595 demonstrated 
the strongest association with a Z score of 4.7 (P = 2.8 × 10−6). The two SNPs in the 
RAP1GAP locus were not associated with AAC in the MESA Hispanic-American cohort 
(Table 2).
There was a modest association between rs2107595 and AAC in African Americans from 
the FamHS (n = 621, Z = 2.5, P = 0.01), with a direction of association consistent with the 
discovery analysis. However, no significant association between SNPs from the HDAC9 
locus and AAC was observed in the MESA African-American cohort (n = 343) or the AA-
DHS (n = 631), or in a meta-analysis combining these three cohorts (Z = 1.41, P = 0.12; 
Supplementary Table 5). There was no association between SNPs in the RAP1GAP locus 
and AAC in the African-American cohorts, although there was limited power to detect an 
association given the small sample sizes of the populations.
To assess whether the genetic determinants of AAC are similar to that of calcification in 
other vascular beds and for cardiovascular disease, we determined whether the SNPs 
associated with AAC were also associated with TAC (n = 8,422), coronary artery 
calcification (in the CHARGE Consortium, n = 9,992)3, carotid artery plaque (in the 
CHARGE Subclinical Atherosclerosis consortium, n = 40,574, unpublished data), and 
clinically apparent coronary heart disease (in the CardiogramPlusC4D Consortium, n = 
193,189)17. All six SNPs in the HDAC9 locus met the genome-wide level of significance for 
association with myocardial infarction, with the strongest association for rs2107595 (P = 8.1 
× 10−11, Supplementary Table 6). rs57301765 was nominally associated with TAC (P = 
0.047), while rs2107595 was associated with coronary artery calcification (P = 0.039). 
Similar to the findings from a previous analysis within the CHARGE consortium of genetic 
association with carotid artery plaque using HapMap (n = 25,179, P = 1.8 × 10−3)18, all six 
SNPs in the HDAC9 locus were associated with the presence of carotid artery plaque in a 
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larger sample size using 1000G imputation19, with the strongest association for rs2107595 
(P = 7.8 × 10−4, Supplementary Table 6). We therefore conclude that SNPs in the HDAC9 
locus may also be associated with vascular disease in the thoracic aorta, coronary arteries, 
and carotid arteries. Previous GWAS have found associations between HDAC9 and large 
vessel ischemic stroke and myocardial infarction17,20,21. Interestingly, other SNPs 
previously known to be associated with stroke, myocardial infarction, or coronary artery 
disease at the genome-wide level22 had significantly weaker associations with AAC (P > 
10−3, Supplementary Table 7) compared to the SNPs in the HDAC9 locus, further 
implicating HDAC9 specifically in the development of abdominal aortic calcification. 
Splicing quantitative trait loci (sQTL) analyses indicated that some minor alleles in the 
HDAC9 locus that are associated with increased AAC are also associated with increased 
expression of certain splicing transcripts of HDAC9 (Supplementary Note).
The acetylation and deacetylation of histones serves as a key determinant of chromatin 
structure and gene transcription and allow for the coupling of extracellular signals with 
genomic architecture23. Histone deacetylases remove acetyl groups from histones and 
consist of a superfamily of eleven enzymes that are further subdivided into four families 
(HDAC class I, IIa, IIb, and IV)24. HDAC9 belongs to the class IIa HDAC family25. To 
examine the role of HDAC9 in vascular calcification, human aortic smooth muscle cells 
(HASMCs) were treated with calcifying media in the presence or absence of TMP269, a 
class IIa HDAC inhibitor26. Compared to HASMCs incubated in normal tissue culture 
medium, HASMCs treated with calcifying medium for 10 days exhibited a >2-fold increase 
in mRNA levels of RUNX2, a master regulator of osteogenic phenotype switch in vascular 
SMCs (Fig. 2a)27. Treatment of HASMCs with TMP269 prevented induction of RUNX2 
expression in response to calcifying medium, and TMP269-treated HASMCs incubated in 
calcifying medium had reduced calcification (Fig. 2a,b). Because TMP269 inhibits all of the 
members in the HDAC class IIa family, we next sought to determine whether specific 
knockdown of HDAC9 mRNA levels with siRNA (siHDAC9) was sufficient to inhibit 
RUNX2 gene induction and in vitro calcification of HASMCs incubated in calcifying media. 
Compared to the effects of control siRNA (siCTRL), siHDAC9 decreased HDAC9 mRNA 
levels by >75%, decreased RUNX2 expression by >50% (Fig. 3a,b), and reduced the in vitro 
calcification of HASMCs treated with calcifying medium (Fig. 3c).
The observation that inhibition of HDAC9 activity reduces RUNX2 expression implicates 
HDAC9 in the development of an osteogenic vascular SMC phenotype, which is associated 
with reduced contractility and increased proliferation28. Therefore, we hypothesized that 
inhibition of HDAC9 gene expression would increase contractility and reduce proliferation 
of vascular SMCs. Treatment of HASMCs with siHDAC9 increased contractility by ~30% 
(P = 0.009) as measured using a cell-embedded collagen gel contraction assay (Fig. 3d)29. 
Furthermore, HASMCs treated for 2 days with siHDAC9 exhibited a ~60% reduction in 
proliferation (Fig. 3e). These results indicate that inhibition of HDAC9 expression favors an 
increased contractile and decreased proliferative vascular smooth muscle cell phenotype.
To determine whether increased expression of HDAC9 promotes an osteogenic vascular 
SMC phenotype, we treated HASMCs with an adenoviral vector expressing HDAC9. 
Treatment of HASMCs with the HDAC9 adenovirus resulted in a 75% increase in RUNX2 
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mRNA after 8 days of treatment (Fig. 3f) and resulted in increased calcification (Fig. 3g). 
Furthermore, treatment of HASMCs with HDAC9 adenovirus reduced contractility (Fig. 
3h). Taken together, these results indicate that increased HDAC9 expression promotes a 
vascular SMC osteogenic phenotype and calcification, and inhibition or decreased levels of 
HDAC9 reduces RUNX2 gene expression and decreases the calcification of HASMCs.
We used a mouse model of vascular calcification caused by matrix Gla protein (MGP) 
deficiency30 to investigate the role of HDAC9 in vascular calcification in vivo, as detailed in 
the Supplementary Note. Compared to Mgp−/− Hdac9+/+ mice, Mgp−/− Hdac9−/− mice 
exhibited a ~50% reduction in aortic Runx2 mRNA levels (P = 0.024) associated with 
reduced disruption of elastin fibers, a ~40% reduction in aortic calcification as assessed by 
near-infrared fluorescent imaging (P = 0.027), and improved survival (Fig. 4a–g and 
Supplementary Fig. 2). Furthermore, primary aortic SMCs isolated from Hdac9−/− mice had 
reduced expression of osteogenic markers and were protected from calcification 
(Supplementary Fig. 3). These results identify HDAC9 as an important contributor to the 
development of vascular calcification in vivo.
In summary, we performed a GWAS with over 9,400 participants and identified a novel 
genetic locus associated with abdominal aortic calcification, a strong and independent 
predictor of cardiovascular disease events. Multiple SNPs in the HDAC9 locus were 
associated with AAC. The association between SNPs in the HDAC9 locus and AAC was 
validated in an independent cohort of Hispanic Americans. These SNPs in the HDAC9 locus 
were associated with other forms of calcification, including thoracic aortic and coronary 
artery calcification. Reducing the expression of HDAC9 or inhibiting its activity prevented 
the in vitro calcification of HASMCs. Furthermore, vascular calcification was significantly 
reduced and survival improved in Mgp−/− mice deficient in HDAC9.
Previous GWAS found an association between HDAC9 and large vessel ischemic stroke, 
myocardial infarction, and increased pulse pressure17,20,21,31. There is also a strong clinical 
link between aortic calcification and these indicators of cardiovascular disease7,32,33. Our 
identification of HDAC9 as an activator of vascular calcification therefore offers a potential 
unifying molecular mechanism for the associations of HDAC9 with stroke, myocardial 
infarction, and pulse pressure. Vascular calcification is characterized by the phenotypic 
transition of vascular smooth muscle cells to osteoblast-like cells that deposit calcium 
phosphate in the extracellular space28,34,35. RUNX2 is a master regulator of this osteogenic 
phenotypic change36,37, which is marked by an increase in vascular smooth muscle cell 
proliferation and reduced cell contractility38. In this study, inhibition of HDAC9 in 
HASMCs prevented calcification induced by calcifying medium. In addition, inhibition of 
HDAC9 reduced RUNX2 expression, decreased cell proliferation, and increased cell 
contractility. Conversely, adenoviral-mediated expression of HDAC9 in HASMCs promoted 
osteogenic phenotype switch and calcification. The results of these functional assays 
underscore an important role for HDAC9 in altering the phenotypic state of vascular smooth 
muscle cells. Further investigation is warranted to determine whether HDAC9 contributes to 
the pathogenesis of a wide range of vascular smooth muscle cell-associated diseases, 
including hypertension, arterial stiffness, and aneurysmal disease21,39 in addition to 
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coronary artery disease and stroke. There are potential limitations to our study, as described 
in the Supplementary Note.
In conclusion, in this translational genomic study, we identified a novel association between 
variants in the HDAC9 locus and AAC. Functional studies implicate HDAC9 as an 
important determinant of vascular smooth muscle cell phenotype and calcification. 
Deficiency of HDAC9 significantly decreased vascular calcification in a mouse model. This 
study is the first to identify a genetic risk locus associated with calcification of the 
abdominal aorta and describes a novel role for HDAC9 in the development of vascular 
calcification. Our findings highlight HDAC9 as a potential target of therapy for vascular 
calcific disease.
Methods
Study design
The Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) 
Consortium is an ongoing investigator-driven collaboration among several large, population-
based cohort studies that have genome-wide genotype data in addition to comprehensive 
individual phenotyping for a variety of endpoints. Details of this collaboration have been 
described previously5,15. We employed a two-stage analysis to first discover and then 
validate the association of genetic loci with the extent of abdominal aortic calcification 
(AAC) and thoracic aortic calcification (TAC). The initial discovery meta-analysis included 
genome-wide association study (GWAS) data from five large population-based cohorts 
including the Framingham Heart Study (FHS), the Age, Gene-Environment Susceptibility-
Reykjavik Study (AGES-RS), the Multi-Ethnic Study of Atherosclerosis (MESA), the 
Family Heart Study (FamHS), and the Heinz Nixdorf Recall (HNR) study. Discovery cohort 
participants were of White European ancestry and had undergone genotyping and computed 
tomography (CT) scanning to assess the presence of, and to quantify, AAC and TAC.
In stage 2, significant findings from this initial meta-analysis were tested in additional multi-
ethnic cohorts, including African American and Hispanic American participants from 
MESA, the FamHS, and the African-American Diabetes Heart Study (AA-DHS).
All cohorts obtained approval from their institutional review board to perform the study and 
individual participant informed consent was obtained. Further details about the discovery 
and validation cohorts are described in the Supplementary Note.
Assessment of aortic calcium
A similar methodology for assessing aortic calcium was used in each of the cohorts, 
according to established standards. Calcium strongly attenuates x-rays, appears bright on CT 
scans, and is readily differentiated from surrounding tissue. Using standard Agatston 
methodology40, a threshold of ≥3 contiguous pixels of ≥130 Hounsfield units brightness was 
used to define calcium in FHS, MESA, FamHS, and AA-DHS, and ≥4 pixels was required in 
HNR. A volume-based approach to calcium measurement was used in AGES-RS and a 
calcium mass score was used in AA-DHS. Agatston score, volumetric assessment, and mass 
score of calcium are widely used and are highly correlated with one another2,41. While 
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individual cohorts used different scanner types, ranging from EBCT to 8-slice MDCT, the 
equivalency of various scanner types and protocols for the detection and quantification of 
calcium has been demonstrated previously42–44. Additionally, all sites used calcium 
phantoms to enhance quality control during image acquisition and analysis.
Statistical analyses
Discovery and replication analyses—For the discovery stage (stage 1), the association 
between each SNP and the extent of AAC and TAC was analyzed in each individual cohort 
independently, using linear regression with adjustments for age, sex, and ancestry (if 
necessary). Both AAC and TAC were analyzed as continuous variables using the log 
transformation of (calcium score + 1). GEE was used in the FHS analyses to account for 
familial correlations. While the FHS, AGES-RS, MESA, and FamHS cohorts provided data 
for AAC, the FHS, AGES-RS, MESA, and HNR cohorts provided data for TAC 
(Supplementary Table 1).
Individual study results were combined using fixed effects meta-analysis as implemented in 
the METAL software45. Given the unequal number of cases and controls in each study, we 
utilized the effective sample size as the weighting scheme. This weighting approach also 
provides the flexibility to allow for different β-coefficients and standard errors from 
individual studies that utilize different measurement units, such as the volumetric scoring in 
AGES-RS compared to the Agatston score in the other discovery cohorts. Heterogeneity 
analysis was also performed with no evidence of heterogeneity found between studies. 
Study-specific results were genomic control corrected, and SNPs with minor allele 
frequency <0.01 or an imputation ratio <0.3 were excluded prior to meta-analysis. Meta-
analysis results were filtered to ensure that ≥2 cohorts contributed to the statistics for each 
SNP. For additional quality assessment, quantile-quantile (Q-Q) plots of the distribution of 
observed versus predicted p-values were created as were Manhattan plots of the SNP P-
values of association relative to the SNP chromosomal location (Fig. 1a and Supplementary 
Fig. 1). To limit the number of false-positive associations given the large number of analyzed 
SNPs, the threshold for statistical genome-wide significance for individual SNP results in 
the discovery analysis was defined a priori as P < 5.0 × 10−8, as is standard for GWAS. 
SNPs with P < 1.0 × 10−6 are also reported as these may generate hypotheses for future 
studies (Supplementary Tables 2 and 3).
Assessment of SNPs for validation study—In the validation stage, the SNPs that met 
genome-wide significance in the discovery analysis were tested in additional cohorts, 
including a multi-ethnic population from MESA, FamHS, and the AA-DHS. As eight SNPs 
were tested for the validation phase, statistical significance was defined using the 
conservative Bonferroni correction as P < 0.05/8 = 0.0062, with a consistent direction of 
association.
Splicing quantitative trait loci (sQTL) analyses—The sQTL analyses were 
conducted using two expression datasets available in the Framingham Heart Study (FHS). 
Firstly, we analyzed 5,257 FHS participants with both 1000G-imputed SNP data and whole 
blood Affymetrix Exon Array expression data by following the same analytic pipeline, as 
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previously described46. Secondly, using whole blood RNA-sequencing data available for 183 
FHS participants, we applied Altrans (Ongen et al. doi: http://dx.doi.org/10.1101/014126) to 
identify significant associations between Ensembl transcripts and SNPs.
Functional and in vivo studies
Animals—This study was carried out in strict accordance with the recommendations in the 
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. 
Housing and all procedures involving mice described in this study were specifically 
approved by the Institutional Animal Care and Use Committees of Massachusetts General 
Hospital (Subcommittee on Research Animal Care, protocol #2008N000169). Mgp+/− mice 
were generated by G. Karsenty and colleagues30. Hdac9−/− mice were generated by E. Olson 
and colleagues47. To investigate the role of HDAC9 in vascular calcification in MGP-
deficient mice, Mgp+/− mice were mated with Hdac9−/− mice to generate Mgp−/− Hdac9−/− 
mice. Animals were maintained on a standard diet. Survival studies were performed and the 
Kaplan-Meier statistic with log-rank testing was used to compare survival of mice.
Calcification of HASMCs—HASMCs were obtained from Cell Applications (#355–75a). 
To induce calcification in HASMCs, cells were treated with DMEM supplemented with 10% 
fetal bovine serum, 10 mM β-glycerophosphate disodium, 50 μg/mL L-ascorbic acid, and 10 
nM dexamethasone, as previously described48. To assess the effects of HDAC9 inhibition on 
calcification, cells were treated with either 100 nM TMP269 (Selleckchem, Cat No. S7324) 
or vehicle (DMSO) control. Media and treatment were replenished every 24 hours for 7–10 
days. Either RNA was isolated from cells to assess mRNA levels (see below) or the cells 
were fixed in 10% formalin and incubated with Alizarin Red or von Kossa stain to detect 
calcification. For Alizarin Red staining, cells were treated with a 2% Alizarin Red solution 
(pH 4.1–4.3) for 20 minutes, followed by multiple washes with distilled water. For von 
Kossa staining, cells were incubated in 5% silver nitrate solution and exposed to a 100 Watt 
bulb for 1–2 hours. Removal of unreacted silver was performed by subsequent treatment 
with 5% sodium thiosulfate. Cells were then washed with distilled water.
siRNA-mediated knockdown and adenovirus-mediated expression of HDAC9
—siRNA directed against HDAC9 (siHDAC9) and scrambled control siRNA (siCTRL) were 
obtained from Dharmacon (SMARTpool, Thermo Scientific). HASMCs were transfected 
with siRNA using Lipofectamine RNAiMAX reagent, as described by the manufacturer 
(Life Technologies).
Recombinant adenoviruses expressing either human wild-type HDAC9 (NM_058176) with a 
C-terminal Enhanced Green Fluorescent Protein (eGFP) tag or expressing eGFP alone were 
obtained from Vector Biolabs (human adenovirus type 5 [dE1/E3], promoter: 
cytomegalovirus, Catalog #1768, Malvern, PA). HASMCs were transduced with the 
adenovirus vectors in regular growth medium. After 24 hours, cells expressing eGFP were 
detected using fluorescent microscopy. RNA and protein levels were analyzed by qPCR and 
Western blot, respectively, 8 days after transduction.
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Proliferation assay—HASMCs were plated in a 96-well format and transfected with 
either siHDAC9 or siCtrl for 48 hours. An MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide)-based assay (ATCC #30–1010K) was used to assess cell 
proliferation. Briefly, 10 μL of the MTT reagent was added to each well, and the plate was 
incubated at 37 °C in a cell culture incubator in the dark for 3 hours, until a purple 
precipitate was visible inside the cells using standard light microscopy. Detergent reagent 
(100 μL) was then added to each well, and the plate was incubated at room temperature in 
the dark for 2 hours before measurement of absorbance at 570 nm.
Collagen matrix cell contraction assay—HASMC contraction was measured by the 
extent of deformation of collagen lattices, as previously described49. Cells were treated with 
siRNA for 24 hours prior to being embedded in collagen matrices, per manufacturer’s 
protocol (Cell Contraction Assay #CBA-201, Cell Biolabs, Inc). After 48 hours, the collagen 
lattice was released from the culture dish. Upon releasing the collagen lattice, the embedded 
cells are free to contract the deformable collagen lattice, resulting in a reduction of the 
lattice surface area. After detachment of the collagen gel lattice from the dish, changes in the 
gel surface area were quantified using Image J software.
Near-infrared imaging and quantification of aortic calcification—Age-matched 
wild-type, Mgp−/− Hdac9+/+, Mgp−/− Hdac9+/−, and Mgp−/− Hdac9−/− mice were injected 
via the tail vein with OsteoSense-680 (PerkinElmer, 5 μl/g each) 24 hours before euthanasia, 
as described previously50,51. Aortas were isolated and analyzed ex vivo by fluorescence 
reflectance imaging using an Odyssey Imaging System (LI-COR Biotechnology, Lincoln, 
NE) and software version 3.0.1652,53.
Aortic immunofluorescence and histology—Aortas were embedded and 
cryopreserved in optimal cutting-temperature medium (Sakura Tissue-Tek, Zoeterwoude, 
Netherlands), and 6-μm sections were prepared54. To detect HDAC9 in aortas, frozen tissue 
sections were fixed in cold 100% methanol and incubated with primary antibody (Abcam, 
#ab59718) specific for a 50-kDa isoform of HDAC9. To determine the association between 
HDAC9 expression and the expression of other HDACs as well as contractile and 
extracellular matrix degradation markers, sections were also treated with antibodies for 
HDAC4 and HDAC7 (Abcam, #ab12171 and ab50212, respectively), SM22α, MYH11 and 
MMP9 (Abcam: #ab14106, ab53219, and ab38898). The location of nuclei was identified by 
staining with 4’,6-diamidino-2-phenylindole (DAPI). Two-dimensional and white light 
images were analyzed using Image J software. Aortas were also fixed in formalin (10%) for 
24 hours prior to paraffinization and sectioning (6 μm). Staining with Verhoeff-Van Gieson 
(Thermo Scientific, MI, USA) was performed for assessment of elastin integrity.
Immunoblot techniques—HASMCs and aortas were homogenized in RIPA buffer 
containing protease and phosphatase inhibitors (Sigma). Lysates (20 μg/lane) were mixed 
with denaturing buffer (1× Laemmli loading buffer with 10% of β-mercaptoethanol) and 
analyzed by SDS–PAGE/Western. Rabbit polyclonal anti-HDAC9 antibodies were used to 
detect the 125-kDa isoform of human HDAC9 in HASMCs (Origene, TA318928). Rabbit 
polyclonal antibodies directed against the murine short isoform of HDAC9 (MITR) were 
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used to detect HDAC9 protein in mouse aortas (Abcam, #ab59718). Rabbit polyclonal 
antibodies directed against glyceraldehyde 3-phosphate dehydrogenase (GAPDH, Cell 
Signaling #2118) were used to detect GAPDH protein. Blots were incubated with 
fluorescent-dye labeled anti-rabbit IgG IRDye 800CW (LI-COR, Lincoln, NE) and protein 
bands were imaged using a LI-COR Odyssey detection system (LI-COR, Lincoln, NE).
Preparation of mouse aortic vascular smooth muscle cells—Vascular smooth 
muscle cells (VSMCs) were isolated from aortas of Hdac9−/− mice and wild-type littermate 
controls, as previously described48,55. Aortas were digested with Type 2 collagenase (175 
U/mL, Worthington) and elastase (1.25 U/mL, Sigma) for 30 minutes, and the adventitial 
layer was removed. Aortas were further digested with collagenase and elastase for 60 
minutes, and cells were plated and maintained in Dulbecco’s Minimum Essential Medium 
(DMEM, Invitrogen) supplemented with 10% fetal bovine serum (FBS, Invitrogen), 100 
units/ml of penicillin, and 100 μg/ml of streptomycin at 37°C with 5% CO2. VSMC lineage 
was confirmed by immunocytochemistry using an antibody directed against α-smooth 
muscle actin (SMA, Sigma). Experiments with VSMCs were performed using cells that 
were passaged between 2–8 times.
Measurement of gene expression by quantitative RT-PCR—Total RNA from 
aortas and cultured cells was extracted by the phenol/guanidinium method56. Reverse 
transcription was performed using the High-Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, Foster City, CA, USA). A Mastercycler ep Realplex (Eppendorf, 
Hamburg, Germany) was used for real-time amplification and quantification of transcripts. 
Relative expression of target transcripts was normalized to levels of 18S ribosomal RNA, 
determined using the relative CT method. Taqman® gene expression assays were used to 
quantify mRNA levels encoding RUNX2, HDAC9, TNAP and COL3A1.
Statistical analysis—Statistical analysis was performed using Graph Pad Prism 5.0 
(GraphPad Software, La Jolla, CA) and Stata 13.0 (StataCorp LLC). The Shapiro-Wilk test 
was used to determine the normality of each continuous variable, and all such variables were 
found to be normally distributed. Data are reported as mean ± s.e.m., unless otherwise 
indicated. Two group comparisons of continuous variables were performed using the two-
tailed Student t test. For more than 2 group comparisons of continuous variables, two-tailed 
one-way analysis of variance (ANOVA) with Sidak post-hoc testing was employed. All in 
vitro experiments were performed at least in duplicate. The Kaplan-Meier statistic with log-
rank testing was used to compare survival of Mgp−/− Hdac9−/− mice and Mgp−/− Hdac9+/+ 
mice. A two-tailed P < 0.05 was considered to indicate statistical significance.
Reporting summary
Further information on research design is available in the Nature Research Life Sciences 
Reporting Summary linked to this article.
Data availability
The summary statistics for the cohorts used in the meta-analysis and validation have been 
placed in dbGaP (accession phs000930), as per the policy of the CHARGE consortium57. 
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The remaining data that support the findings of this study are available from the 
corresponding author upon request.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1 |. Polymorphisms in the HDAC9 and RAP1GAP loci are associated with abdominal 
aortic calcification.
a, Manhattan (left) and Quantile-Quantile (right) plots for the association of abdominal 
aortic calcification with ~9 million SNPs in the GWAS meta-analysis of 9,417 participants. 
The hashed line indicates the genome-wide threshold for significance (P < 5 × 10−8). b, 
Regional SNP association map of the HDAC9 genetic region on chromosome 7 observed in 
the GWAS meta-analysis, centered around the lead SNP rs57301765. c, Regional association 
map of the RAP1GAP genetic region on chromosome 1, centered around the lead SNP 
rs4654975.
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Figure 2 |. Inhibition of class IIa HDAC activity prevents osteogenic phenotype switch and 
calcification of cultured vascular smooth muscle cells.
HASMCs were grown in normal or osteogenic media (see Methods) in the presence or 
absence of TMP269 (100 nM) for either 6 or 10 days and harvested for gene expression 
analysis and calcification assessment, respectively. a, Treatment with calcification media 
increased RUNX2 mRNA levels (an important regulator of osteogenic phenotype switch) in 
HASMCs >2-fold. However, treatment with the HDAC inhibitor TMP269 prevented this 
increase in RUNX2 expression (n = 5 biologically independent samples for each group). 
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Statistical comparisons were made using a two-tailed one-way ANOVA with Sidak’s test for 
multiple comparisons. Mean ± s.e.m. is depicted. b, Treatment of HASMCs with 
calcification media for 10 days resulted in calcification, as evidenced by Alizarin Red and 
von Kossa staining. Calcification of HASMCs was inhibited by TMP269. Two independent 
experiments were performed with representative images shown. Scale bar, 1 cm.
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Figure 3 |. Vascular smooth muscle cell calcification, RUNX2 expression, proliferation, and 
contractility are affected by changes in HDAC9 expression.
a-c, Treatment of HASMCs (n = 6 biologically independent samples in each group) grown 
in osteogenic media with siHDAC9 (resulting in >75% knockdown of HDAC9 mRNA) (a) 
reduced RUNX2 mRNA levels by >50% (b) and prevented calcification, as evidenced by 
decreased Alizarin Red and von Kossa staining (c). In a and b, statistical comparisons were 
made using a two-tailed one-way ANOVA with Sidak’s test for multiple comparisons. In c, 
three independent experiments were performed with representative images shown. d, 
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Reduced HDAC9 expression in HASMCs grown in collagen discs (right panel) resulted in a 
~30% increase in contraction (left panel, n = 6 biologically independent samples in each 
group). e, Treatment of HASMCs with 20 nM siHDAC9 resulted in a 60% reduction in 
proliferation (n = 6 biologically independent samples in each group). f, Adenoviral 
expression of the 125-kDa isoform of HDAC9 fused to GFP in HASMCs was associated 
with a 75% increase in RUNX2 mRNA levels, when cells were harvested 8 days after viral 
transduction (n = 12 biologically independent samples in each group). Increased expression 
of HDAC9 was confirmed by Western blot (lower panel) using antibodies directed against 
HDAC9 and GAPDH (for a loading control). A full scan of the blot is in Supplementary 
Figure 4a. g, As shown by Alizarin Red staining, increased HDAC9 expression resulted in 
augmented calcification in HASMCs. Two independent experiments were performed with 
representative images shown. h, Increased HDAC9 expression also caused a 34% decrease 
(left panel, n = 6 biologically independent samples in each group) in contraction of 
HASMCs grown in collagen discs (right panel). In d-f and h, statistical comparisons were 
made using a two-tailed Student t test. Mean ± s.e.m. is depicted in all plots. For c and g, 
scale bar is 1 cm. For d and h, scale bar is 0.5 cm.
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Figure 4 |. HDAC9 deficiency protects against the development of vascular calcification and 
aortic elastin disruption and improves survival in Mgp−/− mice.
a, Longitudinal sections of aortas stained with Verhoeff-Van Gieson (VVG) are depicted, 
showing elastin fiber integrity in the aortas of wild-type, Mgp−/− Hdac9+/+, Mgp−/− 
Hdac9+/−, and Mgp−/− Hdac9−/− mice. The disruption of elastin fiber integrity seen with 
MGP deficiency was improved with HDAC9 deficiency. b, Longitudinal sections of aortas 
isolated from 14-day-old wild-type, Mgp−/− Hdac9+/+, Mgp−/− Hdac9+/−, and Mgp−/− 
Hdac9−/− mice were stained for HDAC9 (red), SM22α (green, a contractile protein), and 
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DNA (blue, DAPI). Increased levels of HDAC9 protein were seen in Mgp−/− Hdac9+/+ 
aortas, and to an intermediate degree in Mgp−/− Hdac9+/− aortas, relative to wild-type aortas. 
HDAC9 localized primarily to nuclei. Increased HDAC9 expression was associated with 
reduced SM22α expression. In a and b, three independent replicates in each group were 
assessed with representative images shown. c, Western blot of proteins isolated from aortas 
of wild-type, Mgp−/− Hdac9+/+, and Mgp−/− Hdac9+/− mice (n = 2 mice in each group) 
confirmed increased levels of the 50-kDa isoform of HDAC9 protein in Mgp−/− Hdac9+/+ 
mice and to a lesser extent in Mgp−/− Hdac9+/− mice compared to wild-type mice. Statistical 
comparison was made using a two-tailed one-way ANOVA with Sidak’s test. A full scan of 
the blot is shown in Supplementary Figure 4b. d, Aortic calcification, as assessed by 
OsteoSense near-infrared imaging (left panel), was reduced by ~40–50% (right panel) in 21-
day-old mice that were deficient in both MGP and HDAC9 (Mgp−/− Hdac9−/−, n = 8) 
compared to Mgp−/− Hdac9+/+ mice (n = 11) and Mgp−/− Hdac9+/− (n = 7) mice. No aortic 
calcification was observed in wild-type mice (n = 7). Scale bar is 1 mm. e, Mgp−/− Hdac9+/+ 
mice (n = 14) had increased aortic Runx2 mRNA levels compared to wild-type mice (n = 7, 
P < 0.0001). Compared to Mgp−/− Hdac9+/+ mice, Mgp−/− Hdac9−/− mice (n = 9) had a 
~50% reduction in aortic Runx2 mRNA levels (P = 0.024). f, Immunofluorescence with an 
antibody directed against MMP9 demonstrated a >60% reduction of MMP9 expression in 
aortic sections from HDAC9-deficient Mgp−/− mice when compared to Mgp−/− Hdac9+/+ 
and Mgp−/− Hdac9+/− mice (n = 3 mice in each group). DAPI (dark blue) was used as a 
nuclear stain. In d-f, statistical comparisons were made using a two-tailed one-way ANOVA 
with Sidak’s test for multiple comparisons. g, Improved Kaplan-Meier survival was 
observed in Mgp−/− Hdac9−/− mice (n = 8) compared to Mgp−/− Hdac9+/+ mice (n = 10, two-
sided log-rank P = 0.0018). For a, b, and f, scale bar is 50 μm. Mean ± s.e.m. is depicted in 
all plots.
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